US Tecfidera Sales Could Plunge By $2.8bn In 2021

Market Reacts To Mylan ‘At-Risk’ Launch

 
• By Dean Rudge

Generic competition to the one of the most lucrative small-molecule opportunities in the US arrived as Mylan pushed on with an “at-risk” launch to Biogen’s Tecfidera. Mylan’s fortunes and the ramifications of parallel litigation in a separate court were speculated by investors in the wake of the news.

Dollars_Pills
Tecfidera revenues will greatly diminish if Mylan and other generics flood the market • Source: Shutterstock

More from Earnings

More from Business